Multiple sclerosis trial results, pancreatic cancer subgroups and heat-health indicators.
Novartis reported that oral remibrutinib reduced annualised relapse rates by 35.2% and 31.2% versus teriflunomide in two trials. The company reported no liver safety signal, an important consideration for this treatment class; approval for multiple sclerosis remains pending.
Why it matters: Adds evidence for a potential oral treatment option, with efficacy and safety both central to its future clinical role.
Read at Reuters →Revolution Medicines presented exploratory analyses from a 500-patient trial showing improved overall survival with Rasonque versus chemotherapy across evaluated RAS mutation subgroups. Benefit was also observed in patients without an identified RAS mutation; these are subgroup findings rather than a separate confirmatory trial.
Why it matters: Helps oncology professionals understand the breadth of the treatment’s evidence while recognising the limits of exploratory analyses.
Read at Reuters →WHO, WMO, UNICEF and UNFPA launched priority indicators for monitoring extreme heat’s effects on pregnant women, newborns and children. The framework links heat exposure with outcomes including preterm birth, stillbirth, pregnancy hypertension and healthcare visits to support earlier action.
Why it matters: Gives health systems practical measures for planning services, identifying vulnerable communities and strengthening heat-health warnings.
Read at WHO →Editorial summaries for general information only; not medical advice. Research findings and company announcements should be read in their original context.